Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681292 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4ELPLLIPG | |
| SCHEMBL18343133 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4ELPLLIPG | |
| SCHEMBL21681323 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4ELPLLIPG | |
| SCHEMBL15638069 | 0.88 | HIF1A (0.49) | HIF1AHSD17B10KDM4EKMT2AGAA | |
| SCHEMBL29577154 | 0.88 | HIF1A (0.49) | HIF1AHSD17B10KDM4EKMT2AGAA | |
| SCHEMBL14241706 | 0.84 | HIF1A (0.52) | HIF1AHSD17B10KDM4ERAB9ALPL | |
| SCHEMBL18343289 | 0.84 | HIF1A (0.46) | HIF1AHSD17B10KDM4EHPGDKMT2A | |
| SCHEMBL18343266 | 0.83 | HIF1A (0.43) | HIF1AKDM4ERAB9AHPGDGSK3A | |
| SCHEMBL18343115 | 0.83 | ALDH1A1 (0.51) | HIF1AHSD17B10KDM4ERAB9ALPL | |
| SCHEMBL18343362 | 0.82 | LMNA (0.49) | HIF1AHSD17B10KDM4EHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210331-A1 | TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | HIF1A 99/4885HSD17B10 1140/4885KDM4E 1909/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | HIF1A 106/4885HSD17B10 1189/4885KDM4E 1871/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | HIF1A 173/4885HSD17B10 1290/4885KDM4E 2096/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | HIF1A 99/4885HSD17B10 1140/4885KDM4E 1909/4885 |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | SLC5A1, SLC2A1, SLC2A4 | HIF1A 1050/4885HSD17B10 1207/4885KDM4E 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.